Bachem

Bachem Expands Multi-Site Production Capacities

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK, and Switzerland

Expert Statement: Torsten Wöhr, Bachem

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Bachem Inks $531 Million Peptides Manufacturing Deal

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531 million – to supply large volumes of peptides following a joint development project. The identity of the customer has not been disclosed.

Bachem Innovates its Manufacturing Capabilities

Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.

Bachem Buys DSM’s Sisslerfeld Site

Swiss peptide and oligonucleotide specialist Bachem has agreed to buy an undeveloped site in Sisslerfeld from DSM. It has completed the purchase of a first plot, with others to follow in the coming years.

Expanding Into Oligonucleotides

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment a few years ago and meanwhile has passed certain milestones on its way to become a preferred oligonucleotide manufacturing partner for pharmaceutical companies.

Expanding Into Oligonucleotides

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment in 2019.

The Importance of Innovation for Future Success

Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.

Bachem and Jitsubo in Licensing Agreement

Swiss CDMO Bachem has signed an exclusive licensing agreement to use the liquid phase peptide manufacturing technology Molecular Hiving developed by Japan’s Jitsubo.

Bachem: Anne-Kathrin Stoller to assume CMO position as of 2018

Swiss biochemicals company Bachem announced that Dr. Anne-Kathrin Stoller will succeed Dr. José de Chastonay as Chief Marketing Officer of the organization on January 1, 2018.

Experts Statements: Dr. Ralph O. Schoenleber, Bachem

Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs. Indeed, medicinal chemists face a challenge of their own. Trying to survive in a changing environment where pharma is focusing on biologics drug candidates will require chemists to adapt.

Modified Peptides

The folded structure of a protein defines its interactions with other molecules. Selective binding ligands could be, e.g., other proteins or peptides. A natural protein consists exclusively of L-amino acids and glycine, and its folded structure is chiral.

Bachem acquires American Peptide Company

Bachem and GlyTech announce co-promotion agreement

Partner for Peptides

Bachem and Debiopharm Sign Follow-up Contract